Insider · CIK 0001362489
Raymond Anderson
Files at MNPR (Monopar Therapeutics). First filing Aug 27, 2026, latest Aug 27, 2026.
Raymond Anderson files SEC Form 4 as director at MNPR (Monopar Therapeutics). Since Aug 27, 2026, Raymond Anderson has reported 0 open-market buys worth $0 and 1 open-market sell worth $351k, the latest filed on Aug 27, 2026.
A track record needs three past buys with six months of prices behind them; Raymond Anderson has 0, so none is measured yet.
The newest scored trade: sold $351k of MNPR on Aug 25, 2026, filed Aug 27, 2026, scored 15 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $351k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
MNPR: Monopar Therapeutics
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Monopar Therapeutics | $351k 3,142 shares | -12% | +264% from low-11% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 25, 2026 | MNPR MONOPAR THERAPEUTICS INC. | 6,284 0.09% of outstanding | $700k | Aug 25, 2026 | none |
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -694 | $110.04 | $76k | 26,169 | Aug 27, 2026 |
| Aug 25, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -646 | $110.07 | $71k | 25,523 | Aug 27, 2026 |
| Aug 25, 2026 | MNPR Monopar Therapeutics | SOpen-market sale Common Stock10b5-1 | -1,802 | $113.05 | $204k | 23,751 | Aug 27, 2026 |
| Dec 2, 2025 | MNPR Monopar Therapeutics | AGrant or award Stock Optionsderivative | +2,924 | $0.00 | $0 | 2,924 | Dec 8, 2025 |
| Mar 4, 2025 | MNPR Monopar Therapeutics | AGrant or award Stock Optionsderivative | +11,365 | $0.00 | $0 | 11,365 | Mar 7, 2025 |
Questions about Raymond Anderson
Answered from the filings on this page, as of the latest one.
Is Raymond Anderson buying or selling?
In the last 12 months Raymond Anderson reported 0 open-market buys worth $0 and 1 open-market sell worth $351k on SEC Form 4; the latest was sold $351k of MNPR on Aug 25, 2026. Grants, option exercises and tax withholding are not counted.
How did Raymond Anderson's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Raymond Anderson has 0.
Where does Raymond Anderson file Form 4?
Raymond Anderson has filed Form 4 at MNPR (Monopar Therapeutics). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.